NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx® to Promote Prescription Avenova
July 19 2021 - 8:00AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
pharmaceutical company focusing on commercializing Avenova for the
eye care market, announces it has partnered with ImprimisRx, one of
the nation’s leading ophthalmology-focused pharmaceutical
businesses, to promote prescription Avenova. ImprimisRx, a wholly
owned subsidiary of Harrow Health, Inc. (Nasdaq: HROW), will
provide NovaBay with national sales, marketing, and distribution
support for its FDA-cleared 0.01% hypochlorous acid Avenova in 40
ml bottles. Avenova is a clinically proven antimicrobial lid and
lash solution for the management of numerous chronic eye
conditions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210719005026/en/
“ImprimisRx has proven success in commercializing high-quality
products through its nationwide customer base of thousands of
ophthalmologists and optometrists, making it an ideal partner for
expanding the reach of Avenova,” said Justin Hall, President and
CEO of NovaBay Pharmaceuticals. “Leveraging our established brand
through this partnership is very exciting. ImprimisRx, through its
highly innovative model, has streamlined the ordering and
delivering of products by eliminating many layers in the
traditional pharmaceutical value chain. Under the new agreement
with ImprimisRx, we can now cost-efficiently expand Avenova’s reach
within the prescription channel by better engaging with
ophthalmologists and optometrists, making prescription Avenova even
more accessible than ever before.”
Avenova addresses a large and rapidly growing dry eye market
that includes 30 million Americans suffering from chronic eye
conditions like blepharitis and meibomian gland dysfunction. It is
the only lid and lash spray formulated with NovaBay’s patented pure
hypochlorous acid and is safe and gentle for everyday use.
Ophthalmologists and optometrists typically prescribe Avenova
before and after cataract and Lasik procedures, making it a
complementary treatment for many of ImprimisRx’s existing
products.
“Avenova is a compelling addition to our expanding ImprimisRx
ophthalmic product portfolio,” said John Saharek, President of
ImprimisRx. “As the only lid and lash spray clinically proven to
address the underlying cause of bacterial dry eye, we believe
Avenova supports our long‑standing commitment to providing
customers with simple and easy access to innovative high-quality
medications. As we have with other partners, we look forward to
working with NovaBay to enhance the commercial success of
prescription Avenova and to significantly build customer demand
within the large and attractive ophthalmic market.”
About ImprimisRx
ImprimisRx is one of the nation’s leading ophthalmology-focused
pharmaceutical businesses, serving thousands of ophthalmologists
and optometrists in all 50 states, with 40 proprietary ophthalmic
formulations. For more information about ImprimisRx, including
product ordering instructions, please visit imprimisrx.com.
About Harrow Health
Harrow Health, Inc. is an ophthalmic-focused healthcare company.
The Company owns and operates ImprimisRx, one of the nation’s
leading ophthalmology-focused pharmaceutical businesses, and
Visionology, a direct-to-consumer eye care subsidiary focused on
chronic eye disease. Harrow Health also holds equity positions in
Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals,
all of which started as Harrow Health subsidiaries. Harrow Health
also owns royalty rights in four clinical stage drug candidates
being developed by Surface Ophthalmics and Melt Pharmaceuticals.
For more information about Harrow Health, please visit the
Investors section of the corporate website, harrowinc.com.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on high-quality, differentiated, anti-infective consumer
products: Avenova®, the premier antimicrobial lid and lash spray,
CelleRx® Clinical Reset™, a breakthrough product in the beauty
category, and NeutroPhase® Skin and Wound Cleanser for wound
healing. NovaBay’s products are formulated with its patented, pure,
stable, pharmaceutical-grade hypochlorous acid that replicates the
antimicrobial chemicals used by white blood cells to fight
infection. NovaBay’s hypochlorous acid products do not cause
stinging or irritation, are non‑toxic and non-sensitizing, making
them completely safe for regular use. Avenova is the only
commercial hypochlorous acid lid and lash spray product clinically
proven to reduce bacterial load on ocular skin surfaces, thus
effectively addressing the underlying cause of bacterial dry
eye.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward‑looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our current
product offerings and marketing efforts, the financial impact of
our partnerships, and any future revenue that may result from
selling these products, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings with the
Securities and Exchange Commission, especially under the heading
“Risk Factors.” The forward-looking statements in this release
speak only as of this date, and NovaBay disclaims any intent or
obligation to revise or update publicly any forward-looking
statement except as required by law.
Harrow Health Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include the impact of the COVID-19 pandemic and any
future health epidemics on our financial condition, liquidity and
results of operations; our ability to make commercially available
our compounded formulations and technologies in a timely manner or
at all; market acceptance of the Company’s formulations and
challenges related to the marketing of the Company’s formulations;
risks related to our compounding pharmacy operations; our ability
to enter into other strategic alliances, including arrangements
with pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Harrow Health’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. Such documents may be read free of charge on
the SEC's web site at www.sec.gov. Undue reliance should not be
placed on forward-looking statements, which speak only as of the
date they are made. Except as required by law, Harrow Health
undertakes no obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210719005026/en/
NovaBay Contacts: At the
Company Justin Hall Chief Executive Officer and General
Counsel 510-899-8800 jhall@novabay.com Investors LHA Investor Relations Jody Cain
310-691-7100 jcain@lhai.com Harrow Health Contact: Jamie
Webb Director of Communications and Investor Relations 615-733-4737
jwebb@harrowinc.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024